Pharmatek has completed installation of a GEA Niro Mobile Minor for the GMP manufacture of amorphous spray dried dispersions and is currently completing equipment validation. The spray dryer complements the company’s purchase of a Gerteis MINI-PACTOR last year.
 
GMP spray drying capabilities will include aqueous and solvent processing in a closed loop system. The spray dryer will be installed in the company’s high containment manufacturing facility, allowing for the manufacture of highly potent and cytotoxic compounds.
 
“Spray drying has become an essential option for anyone specializing in the development of poorly soluble compounds. Over the past five years, we’ve developed a tremendous amount of expertise in amorphous dispersion development for poorly soluble compounds,” said Jeffrey Bibbs, chief executive officer and chief scientific officer of Pharmatek. “This increased capacity allows Pharmatek to offer spray drying support through Phase IIb clinical studies.”